Exelixis ( (EXEL) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exelixis shares came under pressure after new data from Merck’s HIF‑2α inhibitor stoked worries about intensifying competition in a key treatment area. Investors fear the stronger rival profile could weigh on Exelixis’ future growth and pricing power.
In response to these competitive concerns, RBC Capital lowered its price target on Exelixis stock to $43 from $46 while maintaining a Sector Perform rating. The move signals that, although analysts see limited upside for now, they are not yet turning outright bearish on the company.
More about Exelixis
YTD Price Performance: 0.52%
Average Trading Volume: 2,645,109
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.44B
For further insights into EXEL stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.